156 related articles for article (PubMed ID: 31648185)
1. Soluble CD105 is prognostic of disease recurrence in prostate cancer patients.
Placencio-Hickok VR; Madhav A; Kim S; Duong F; Angara B; Liu Z; Bhowmick NA
Endocr Relat Cancer; 2020 Jan; 27(1):1-9. PubMed ID: 31648185
[TBL] [Abstract][Full Text] [Related]
2. Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer.
Vidal AC; Duong F; Howard LE; Wiggins E; Freedland SJ; Bhowmick NA; Gong J
Anticancer Res; 2020 Mar; 40(3):1459-1462. PubMed ID: 32132043
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy.
Arslan B; Onuk Ö; Hazar İ; Aydın M; Çilesiz NC; Eroglu A; Nuhoglu B
Tumori; 2017 Mar; 103(2):204-208. PubMed ID: 27470607
[TBL] [Abstract][Full Text] [Related]
4. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
5. Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen.
Shinghal R; Yemoto C; McNeal JE; Brooks JD
Urology; 2003 Feb; 61(2):380-5. PubMed ID: 12597952
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate-specific antigen.
Miyake H; Hara I; Kurahashi T; Muramaki M; Yamanaka K; Inoue TA; Fujisawa M
Urol Int; 2006; 77(3):200-4. PubMed ID: 17033205
[TBL] [Abstract][Full Text] [Related]
7. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
8. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
9. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
10. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
11. [-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report.
De Luca S; Passera R; Sottile A; Fiori C; Scarpa RM; Porpiglia F
BMC Urol; 2016 Mar; 16():14. PubMed ID: 27013515
[TBL] [Abstract][Full Text] [Related]
12. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy.
Lowe BA; Lieberman SF
J Urol; 1997 Oct; 158(4):1452-6. PubMed ID: 9302141
[TBL] [Abstract][Full Text] [Related]
13. Recurrence after radical prostatectomy for organ-confined prostate cancer.
Scheepe JR; Vis AN; Mickisch GH
Onkologie; 2003 Aug; 26(4):330-3. PubMed ID: 12972697
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging.
Liauw SL; Pitroda SP; Eggener SE; Stadler WM; Pelizzari CA; Vannier MW; Oto A
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):378-84. PubMed ID: 22717242
[TBL] [Abstract][Full Text] [Related]
15. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
[TBL] [Abstract][Full Text] [Related]
16. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.
Miyata Y; Mitsunari K; Asai A; Takehara K; Mochizuki Y; Sakai H
Prostate; 2015 Jan; 75(1):84-91. PubMed ID: 25307287
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of postoperative nadir prostate-specific antigen value by ultrasensitive assay as a predictor of prostate-specific antigen relapse for pathological T3 or positive surgical margins after radical prostatectomy for prostate cancer.
Yoshida T; Matsuzaki K; Kobayashi Y; Takeda K; Nakayama M; Arai Y; Kakimoto K; Nishimura K
Int Urol Nephrol; 2012 Apr; 44(2):479-85. PubMed ID: 21822599
[TBL] [Abstract][Full Text] [Related]
18. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
20. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
